Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Revenue projections:

Revenue projections for DIVISLAB
Revenue projections for DIVISLAB

With DIVISLAB's revenues forecasted to be lower than last year's, investors are expected to be cautious. A decline in revenue typically harms the company's bottom line, reducing profitability and making investors less confident about the company's ability to sustain its financial health.

Financial Ratios:

currentRatio 0.00000
forwardPE 55.66958
debtToEquity 0.58400
earningsGrowth -0.01000
revenueGrowth 0.12300
grossMargins 0.61654
operatingMargins 0.29647
trailingEps 93.64000
forwardEps 116.90407

DIVISLAB's forward PE being elevated could limit price appreciation and heighten the risk of a correction. Investors need to carefully assess this parameter in combination with other fundamentals to determine whether the stock is overvalued.
Divi's Laboratories Limited's positive gross and operating margins indicate healthy profitability. These margins reflect the company's ability to generate income efficiently from its operations, signaling strong financial performance and effective cost management.
With a forward EPS greater than its trailing EPS, Divi's Laboratories Limited is forecasted to be more profitable this year than last. This growth expectation reflects confidence in the company's earnings potential and suggests an improving financial trajectory for the year ahead.

Price projections:

Price projections for DIVISLAB
Price projections for DIVISLAB

DIVISLAB's price projections have been gradually revised upward, reflecting increased confidence in the company's future performance. This trend suggests analysts expect DIVISLAB to achieve greater success in the coming periods.

Insider Transactions:

Insider Transactions for DIVISLAB
Insider Transactions for DIVISLAB


DIVISLAB experienced 8 selling transactions, with market price of 6441.162536621094.During the period under consideration, there were no sell transactions.The trend of more buys compared to sells around Divi's Laboratories Limited's current price levels may signal investor optimism. This behavior suggests that the market is expecting a favorable outcome for the stock, leading to increased buying activity.

Recommendation changes over time:

Recommendations trend for DIVISLAB
Recommendations trend for DIVISLAB


Analysts have shown a buy bias for DIVISLAB, marking it as a favorable investment option. This could inspire investors to see DIVISLAB as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.